Department of Otolaryngology-Head and Neck Surgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Clin Rheumatol. 2013 Mar;32 Suppl 1:S75-7. doi: 10.1007/s10067-010-1501-8. Epub 2010 Jun 8.
A patient with severe Behcet's disease (BD) was referred to our clinic because of severe pharyngolaryngeal involvement. This complication developed under treatment of prednisone and etanercept (Enbrel) 25 mg twice a week. A surgical approach was considered, but following three daily doses of Solu-Medrol (500 mg each) and 300 mg infliximab on the fourth day, the patient improved significantly. This is the first case reporting treatment with infliximab in laryngeal involvement of BD. Although some cases may still require surgical intervention, the therapeutic option of anti-TNF agents, specifically anti-TNF antibodies such as infliximab, may decrease the need for the surgical option.
一位患有严重白塞病（BD）的患者因严重的咽喉受累而被转介至我们诊所。该并发症是在泼尼松和依那西普（Enbrel）每周两次 25 毫克治疗下发生的。考虑采用手术方法，但在第四天给予每日三次的甲泼尼龙（每次 500 毫克）和 300 毫克英夫利昔单抗后，患者的病情显著改善。这是首例报告用英夫利昔单抗治疗 BD 喉受累的病例。虽然有些病例可能仍需要手术干预，但抗 TNF 药物的治疗选择，特别是抗 TNF 抗体，如英夫利昔单抗，可能会降低对手术选择的需求。
